Biosurgery

Global Biosurgery Market to Reach US$18.4 Billion by 2030

The global market for Biosurgery estimated at US$14.5 Billion in the year 2024, is expected to reach US$18.4 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Bone Graft Substitutes, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$7.2 Billion by the end of the analysis period. Growth in the Hemostatic Agents segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.9 Billion While China is Forecast to Grow at 3.9% CAGR

The Biosurgery market in the U.S. is estimated at US$3.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2030 trailing a CAGR of 3.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Biosurgery Market - Key Trends and Drivers Summarized

What Is Biosurgery, and Why Is It Gaining Traction in Modern Medicine?

Biosurgery is an innovative and rapidly evolving field within medical technology, but what exactly does it encompass? Broadly speaking, biosurgery involves the use of biologically-based or biocompatible materials to aid in surgical procedures. These materials are engineered to interact seamlessly with the human body, promoting healing, minimizing complications, and often providing alternatives to traditional surgical methods. The scope of biosurgery is extensive, covering areas such as hemostasis (the process of stopping bleeding), tissue regeneration, and even the use of bioactive implants that can integrate with living tissues. The growing emphasis on less invasive procedures, combined with the desire for faster recovery times and reduced hospital stays, has significantly increased interest in biosurgical techniques. As healthcare systems across the globe prioritize patient outcomes and cost-effectiveness, biosurgery is poised to become a cornerstone of modern surgical practice.

How Are Cutting-Edge Technologies Shaping the Future of Biosurgery?

The landscape of biosurgery is being dramatically transformed by advancements in technology, but how exactly are these changes unfolding? One of the most significant developments has been in the field of regenerative medicine, where biosurgical products such as scaffolds and growth factors are used to facilitate the repair or replacement of damaged tissues. Additionally, the integration of nanotechnology is allowing for the creation of more sophisticated biomaterials that can deliver drugs or other therapeutic agents directly to the site of surgery, enhancing the body`s natural healing processes. Robotics and imaging technologies are also playing a crucial role, providing surgeons with unprecedented precision and control during procedures. Furthermore, the advent of 3D printing is opening up new possibilities for custom implants and grafts that are tailored to individual patients, reducing the risk of rejection and improving outcomes. As these technologies continue to evolve, the potential applications of biosurgery are expanding, promising to revolutionize the way surgeries are performed.

Why Is Biosurgery Becoming the Go-To Option for Complex Surgical Cases?

The unique capabilities of biosurgical products are driving their adoption in complex and challenging surgical cases, but what makes them so indispensable? In many instances, traditional surgical methods are either too invasive or unable to achieve the desired outcomes, particularly in cases involving extensive tissue damage or delicate structures. Biosurgical products, such as fibrin sealants, collagen-based matrices, and synthetic grafts, provide surgeons with tools that can enhance the body`s natural ability to heal, reduce the risk of complications, and improve the overall success rate of surgeries. For example, in cardiovascular surgery, biosurgery is playing a pivotal role in the repair of blood vessels and the prevention of excessive bleeding. In orthopedic surgery, bioactive materials are being used to promote bone regeneration and improve the integration of implants. Moreover, biosurgery is finding increasing applications in wound care, particularly in chronic wounds that are resistant to conventional treatments. As the healthcare industry continues to grapple with the challenges of an aging population and the rising prevalence of chronic diseases, the role of biosurgery in managing these conditions is set to grow.

What Is Fueling the Rapid Expansion of the Biosurgery Market?

The growth in the biosurgery market is driven by several factors, each contributing to the increasing demand for these advanced surgical solutions. Technological innovations, particularly in biomaterials and regenerative medicine, have significantly expanded the range of applications for biosurgery, making it a more viable option across various medical disciplines. Additionally, the rising prevalence of chronic diseases, such as diabetes and cardiovascular conditions, is leading to an increase in complex surgical cases where traditional methods may fall short. Consumer behavior is also playing a role, with patients increasingly seeking out minimally invasive procedures that offer quicker recovery times and fewer side effects. The growing awareness and acceptance of biosurgery among healthcare providers further drive its adoption, as more clinicians recognize the benefits of these techniques in improving patient outcomes. Moreover, the aging global population is contributing to the demand for biosurgical products, as older patients are more likely to require surgical interventions that benefit from these advanced technologies. Finally, supportive government policies and increased investment in healthcare infrastructure, particularly in emerging markets, are providing the necessary environment for the biosurgery market to thrive, ensuring continued growth and innovation in this exciting field.

SCOPE OF STUDY:

The report analyzes the Biosurgery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Bone Graft Substitutes, Hemostatic Agents, Soft Tissue Attachments, Surgical Sealing Agents, Anti-Adhesion Agents); Application (General Surgery, Orthopedic Surgery, Reconstructive Surgery, Gynecological Surgery, Other Applications); End-Use (Hospitals, Clinics, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 12 Featured) -

• B. Braun Melsungen AG
• BARD, A Becton, Dickinson Company
• Baxter International, Inc.
• Cohera Medical, Inc.
• CryoLife, Inc.
• Hemostasis, LLC
• Integra LifeSciences Holdings Corporation
• Johnson & Johnson
• MAQUET Holding B.V. & Co. KG
• Medtronic PLC
• Pfizer, Inc.
• Sanofi U.S.
• Stryker Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.